First amyloid β1‐42 certified reference material for re‐calibrating commercial immunoassays
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction: Reference materials based on human cerebrospinal fluid were certified for the mass concentration of amyloid beta (Aβ)1‐42 (Aβ 42). They are intended to be used to calibrate diagnostic assays for Aβ 42. Methods: The three certified reference materials (CRMs), ERM‐DA480/IFCC, ERM‐DA481/IFCC and ERM‐DA482/IFCC, were prepared at three concentration levels and characterized using isotope dilution mass spectrometry methods. Roche, EUROIMMUN, and Fujirebio used the three CRMs to re‐calibrate their immunoassays. Results: The certified Aβ 42 mass concentrations in ERM‐DA480/IFCC, ERM‐DA481/IFCC, and ERM‐DA482/IFCC are 0.45, 0.72, and 1.22 μg/L, respectively, with expanded uncertainties (k = 2) of 0.07, 0.11, and 0.18 μg/L, respectively. Before re‐calibration, a good correlation (Pearson's r > 0.97), yet large biases, were observed between results from different commercial assays. After re‐calibration the between‐assay bias was reduced to < 5%. Discussion: The Aβ 42 CRMs can ensure the equivalence of results between methods and across platforms for the measurement of Aβ 42.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · cited 12×
“From each vial, three subsamples were measured by ELISA (EUROIMMUN beta-amyloid [1-42], EUROIMMUN AG, Luebeck).”
MethodInfluentialSelf-citationPassing, H., & Bablok, W. (1983) · cclm · doi:10.1515/cclm.1983.21.11.709 · Cited by 1,513
Hansson, O., Seibyl, J., Stomrud, E., Zetterberg, H., Trojanowski, J. Q., Bittner, T., Lifke, V., Corradini, V., Eichenlaub, U., Batrla, R., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.01.010 · Cited by 808 · cited 12×
“From each vial, three subsamples were measured by ELISA (EUROIMMUN beta-amyloid [1-42], EUROIMMUN AG, Luebeck).”
MethodInfluentialSelf-citationAmyloid biomarkers in Alzheimer's disease
Blennow, K., Mattsson, N., Schöll, M., Hansson, O., & Zetterberg, H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.002 · Cited by 470 · cited 12×
“From each vial, three subsamples were measured by ELISA (EUROIMMUN beta-amyloid [1-42], EUROIMMUN AG, Luebeck).”
MethodInfluentialSelf-citationBittner, T., Zetterberg, H., Teunissen, C. E., Ostlund, R. E., Militello, M., Andreasson, U., Hubeek, I., Gibson, D., Chu, D. C., Eichenlaub, U., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.09.009 · Cited by 374 · cited 12×
“From each vial, three subsamples were measured by ELISA (EUROIMMUN beta-amyloid [1-42], EUROIMMUN AG, Luebeck).”
MethodInfluential
Cited by
Blood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationDeveloping the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Self-citationHampel, H., Hu, Y., Cummings, J., Mattke, S., Iwatsubo, T., Nakamura, A., Vellas, B., O’Bryant, S., Shaw, L. M., Cho, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.017 · Cited by 283
Self-citationMielke, M. M., Frank, R. D., Dage, J. L., Jeromin, A., Ashton, N. J., Blennow, K., Karikari, T. K., Vanmechelen, E., Zetterberg, H., Algeciras-Schimnich, A., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.2293 · Cited by 244
Self-citationMoving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
Zetterberg, H., & Blennow, K. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00430-x · Cited by 219
“Reference methods and materials for CSF Aβ42 assay standardization [10], as well as high-precision clinical chemistry tests on fully automated instruments, are in place [60], which bodes well for full implementation of these biomarkers in clinical laboratory practice with Zetterberg and Blennow Molecular Neurodegenera…”
MethodSelf-citation
Metadata
- Authors
- Boulo, S., Kuhlmann, J., Andreasson, U., Brix, B., Venkataraman, I., Herbst, V., Rutz, S., Manuilova, E., Vandijck, M., Dekeyser, F., Bjerke, M., Pannee, J., Charoud‐Got, J., Auclair, G., Mazoua, S., Pinski, G., Trapmann, S., Schimmel, H., Emons, H., Quaglia, M., Portelius, E., Korecka, M., Shaw, L. M., Lame, M., Chambers, E., Vanderstichele, H., Stoops, E., Leinenbach, A., Bittner, T., Jenkins, R. G., Kostanjevecki, V., Lewczuk, P., Gobom, J., Zetterberg, H., Zegers, I., & Blennow, K.
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2020-08-04
- Volume
- 16
- Issue
- 11
- Pages
- 1493-1503
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3047014868
- Cited by
- 65
- References
- 6
- FWCI
- 6.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.